● Presence of manic/hypomanic episodes that may alternate with depressive episodes
● overconfidence, grandiosity, talkativeness, extreme disinhibition, irritability, decreased
need for sleep, and highly elevated mood
● Psychotic symptoms such as delusions and hallucinations occur in up to 75% of manic
episodes
● Bipolar I : manic episodes
● Bipolar II : hypomanic episodes
● The presence of at least one hypomanic episode in a life trajectory is considered to be
consistent with the diagnosis of bipolar II disorder
● Cyclothymic disorder is characterized by recurrent depressive and hypomanic states,
lasting for at least 2 years, that do not meet the diagnostic threshold for a major affective
episode
● DSM : symptoms must be present for 1 week for a diagnosis of a manic episode or 2
weeks for diagnosis of depressive episode
● Onset : 20 years
● An earlier onset is often associated with a poorer prognosis, longer treatment delays,
more severe depressive episodes, and higher prevalences of concurrent anxiety and
substance use disorders
● First episode usually depressive - misclassified as major depressive disorder
● In a ⅓ of affected persons not diagnosed until 10 years after onset
Epidemiology and burden
● Lifetime prevalence 2.4%
● 12 month prevalence 1.5%
● Prevalence varies by country
● Bipolar I M=W
● Bipolar II W>M
● Tentative associations between IBS, childhood adversity and bipolar disorder
● Cognitive and psychosocial dysfunction during acute episode
● 6-7% commit suicide
● High rates of comorbid disorders
○ Anxiety
○ Substance use
○ Personality disorder
○ Adhd
● Metabolic syndrome, migraine, obesity, type 2 diabetes more common
● Twice the risk of death (suicide/medical condition)
,Genetic and neurobiological features
● Common variants of genetic risk only account for 25% of heritability
● Gene-environment interaction
● Kindling hypothesis : first episode due to stressor, subsequent episodes can occur
without exposure to stressor
● Poorly characterized epigenetic mechanisms contribute to kindling phenomenon
● Progressive changes in brain structure → reduced cortical thickness in pfc, pathways
subserving neuroplasticity, inflammation, increase in stress
● Deregulation of mitochondrial function
● Aberrations in HPA AXIS → Pathophysiology and progression of bipolar disorder
● Neuroprogression → worsening of cognitive and functional impairments
● Prevalence of type 2 diabetes higher in people with multi episode bipolar
● As bipolar illness progresses, the response to mood stabilizing medications may
decrease
, Management
● Primary care practice improve mental and physical health outcomes
● Medical and psychiatric conditions that mimic affective episodes should be ruled out
during diagnostic assessment
● Selection of initial treatment : patient’s preference, coexisting medical and psychiatric
conditions, previous responses to treatment
● During acute affective episodes the safety of the patient should be ensured
● Evidence based pharmacologic interventions
Treatment of acute episodes
● Acute mania
○ Antipsychotic agents/mood stabilizers
○ If there is no response to a medication after ½ weeks a different medication may
be considered
○ Antipsychotic + mood stabilizer for severe mania
○ In children risperidone > lithium
○ A lot of metabolic adverse depression
○ Haloperidol, paliperidone
○ Electroconvulsive therapy
● Acute depression
○ A low initial dose with gradual upward dose adjustment
○ Combination therapies = antipsychotics and mood stabilizers
○ Rct :ketamine
○ Affective switches - treatment with antidepressants may carry a risk of switches
to hypomania/mania + accelerated cycling between them
○ Second generation antidepressants (SSRIs) may be effective for short term
management of bipolar disorder
○ Risk of mania switches higher in Bipolar I patients → antidepressants avoided
○ Ect effective for patients with treatment resistant and multitherapy resistant
bipolar depression
○ Psychoeducation, cbt, family focused therapy, DBT, MBCT, ITP, social rhythm
therapy
○ children/adolescents : family education + CBT
● Maintenance treatment
○ Combination of pharmacologic, psychological and lifestyle interventions
○ Ideally maintenance treatment started shortly after onset of illness
○ Lithium monotherapy more effective in preventing manic and depressive
episodes
■ Side effects : renal failure, hypothyroidism, polydipsia, tremors, increase
in parathyroid hormone levels
○ Meta Analysis : lithium, antipsychotics may reduce long term morbidity in juvenile
bd
○ Side effects
○ Divalproex - teratogen → not recommended for women of childbearing age
○ Maintenance ect
Alle Vorteile der Zusammenfassungen von Stuvia auf einen Blick:
Garantiert gute Qualität durch Reviews
Stuvia Verkäufer haben mehr als 700.000 Zusammenfassungen beurteilt. Deshalb weißt du dass du das beste Dokument kaufst.
Schnell und einfach kaufen
Man bezahlt schnell und einfach mit iDeal, Kreditkarte oder Stuvia-Kredit für die Zusammenfassungen. Man braucht keine Mitgliedschaft.
Konzentration auf den Kern der Sache
Deine Mitstudenten schreiben die Zusammenfassungen. Deshalb enthalten die Zusammenfassungen immer aktuelle, zuverlässige und up-to-date Informationen. Damit kommst du schnell zum Kern der Sache.
Häufig gestellte Fragen
Was bekomme ich, wenn ich dieses Dokument kaufe?
Du erhältst eine PDF-Datei, die sofort nach dem Kauf verfügbar ist. Das gekaufte Dokument ist jederzeit, überall und unbegrenzt über dein Profil zugänglich.
Zufriedenheitsgarantie: Wie funktioniert das?
Unsere Zufriedenheitsgarantie sorgt dafür, dass du immer eine Lernunterlage findest, die zu dir passt. Du füllst ein Formular aus und unser Kundendienstteam kümmert sich um den Rest.
Wem kaufe ich diese Zusammenfassung ab?
Stuvia ist ein Marktplatz, du kaufst dieses Dokument also nicht von uns, sondern vom Verkäufer stasamilenkovic2002. Stuvia erleichtert die Zahlung an den Verkäufer.
Werde ich an ein Abonnement gebunden sein?
Nein, du kaufst diese Zusammenfassung nur für 6,49 €. Du bist nach deinem Kauf an nichts gebunden.